TUKYSA® (tucatinib) tablets, a HER2-directed treatment option for patients with certain HER2-positive cancers. Read full Indication and Important Safety Information.

Learn about the dosing and administration of TUKYSA® (tucatinib) tablets + trastuzumab + capecitabine. Read full Indication and Important Safety Information.

TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

See the efficacy and safety data of the TUKYSA® (tucatinib) tablets regimen from the MOUNTAINEER trial. Read full Indication and Important Safety Information.

Learn about TUKYSA® (tucatinib) tablets, HER2CLIMB, efficacy data, safety profile, dosing, and more. Read full Indication and Important Safety Information.

See the safety profile of TUKYSA® (tucatinib) tablets + trastuzumab + capecitabine. Read full Indication and Important Safety Information.

TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

View efficacy data for TUKYSA® (tucatinib) tablets, in combination with trastuzumab + capecitabine. Read full Indication and Important Safety Information.

TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.